Objective To investigate the effect of up-regulation of long-chain non-coding RNA GHET1 on the prognosis of liver transplantation patients with hepatocellular carcinoma, and to explore whether it can be used as a potential molecular target for the detection and treatment of liver transplantation for liver cancer. Methods Twenty samples of hepatocellular carcinoma and corresponding cancer adjacent tissues were collected. The samples of hepatocellular carcinoma from 106 patients who underwent orthotopic liver transplantation were collected. Theywere divided into recurrence group and non-recurrence group according to whether there was a recurrence of hepatic carcinoma. According to the expression of GHET1, they were divided into the high expression group and low expression group. Quantitative real-time PCR （qRT-PCR） was used to detect the expression of GHET1 in all tissues. The relationships between GHET1 expression, the clinicopathological features and prognosis of HCC were analyzed. Results Compared with the adjacent non-tumor tissues, the expression of GHET1 was increased in hepatocellular carcinoma（P ＜ 0.001）. The results of clinical pathology analysis showed that GHET1 expression was closely related with tumor capsule （P ＜ 0.001）， tumor diameter （P ＜ 0.01）， differentiation grade （P ＜ 0.01）， vascular invasion（P ＜ 0.01） and TNM stage（P ＜ 0.01），but not related to the patient's age， gender， cirrhosis， serum AFP levels， serum NLR values， tumor location and tumor number （P ＞ 0.05）. In 106 liver cancer patients who underwent liver transplantation, the expressions of GHET1 were significantly higher in the recurrence group compared to the non-recurrence group （P ＜ 0.001） and the low-expression group. The cumulative recurrence rate in the high-expression group was significantly higher （P ＜ 0.05）. The cumulative survival rate in the high-expression group was significantly lower （P ＜ 0.001）. The difference was statistically significant. Conclusion GHET1 overexpression is associated with clinicopathological feature and poor prognosis. This conclusion suggests that GHET1 may be involved in the occurrence and development of HCC, and it can be used as a prognostic marker and clinical target in liver cancer patients who undergo liver transplantation.